Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Abeprazan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abeprazan SCHEMBL29719476 | 1.00 | HTR6 (0.39) | HTR6DRD2MEN1GFERKMT2A | |
| Abeprazan SCHEMBL18196939 | 1.00 | HTR6 (0.39) | HTR6DRD2MEN1GFERKMT2A | |
| Abeprazan SCHEMBL19385615 | 0.99 | HTR6 (0.40) | HTR6DRD2MEN1GFERKMT2A | |
| Abeprazan SCHEMBL29201776 | 0.97 | HTR6 (0.38) | HTR6DRD2MEN1GFERKMT2A | |
| Abeprazan SCHEMBL29201774 | 0.95 | HTR6 (0.37) | HTR6DRD2MEN1GFERKMT2A | |
| Abeprazan SCHEMBL19385601 | 0.94 | FABP4 (0.38) | HTR6DRD2MEN1GFERKMT2A | |
| SCHEMBL18190937 | 0.93 | HTR6 (0.35) | HTR6DRD2MEN1GFERKMT2A | |
| SCHEMBL18196931 | 0.93 | HTR6 (0.40) | HTR6DRD2HTR2ASMN1; SMN2 | |
| Abeprazan SCHEMBL19385619 | 0.93 | HTR6 (0.37) | HTR6DRD2MEN1GFERKMT2A | |
| Hydrochloric Acid SCHEMBL20530226 | 0.92 | HTR6 (0.40) | HTR6DRD2HTR2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090593-A2 | RNA BIOMARKERS FOR USE IN BARRETT'S ESOPHAGUS | CITY OF HOPE (US) | 2026-04-30 | — | — | WO | claimed |
| US-20250268862-A1 | POTASSIUM-COMPETITIVE ACID BLOCKERS FOR THE TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-08-28 | — | — | US | claimed |
| WO-2023211843-A1 | POTASSIUM-COMPETITIVE ACID BLOCKERS FOR THE TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-02 | — | — | WO | claimed |
| WO-2026090593-A2 | RNA BIOMARKERS FOR USE IN BARRETT'S ESOPHAGUS | CITY OF HOPE (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260060966-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER AG (DE) | 2026-03-05 | — | — | US | disclosed |
| US-20260048041-A1 | COMPOSITION FOR REMOVING HELICOBACTER PYLORI COMPRISING ZASTAPRAZAN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | JEIL PHARMACEUTICAL CO LTD (KR) | 2026-02-19 | — | — | US | disclosed |
| US-20260027091-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER AG (DE) | 2026-01-29 | — | — | US | disclosed |
| EP-4450060-A4 | DOSAGE REGIMEN FOR FEXUPRAZAN INJECTION COMPOSITION | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2025-10-22 | — | — | EP | disclosed |
| US-20250313559-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2025-10-09 | — | — | US | disclosed |
| EP-4628081-A1 | COMPOSITION FOR REMOVING HELICOBACTER PYLORI COMPRISING ZASTAPRAZAN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Jeil Pharmaceutical Co., Ltd. (KR) | 2025-10-08 | — | — | EP | disclosed |
| US-20250302811-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER HEALTHCARE PHARMACEUTICALS INC. | 2025-10-02 | — | — | US | disclosed |
| WO-2023113487-A1 | DOSAGE REGIMEN FOR FEXUPRAZAN INJECTION COMPOSITION | 주식회사 대웅제약 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023113487-A1 | DOSAGE REGIMEN FOR FEXUPRAZAN INJECTION COMPOSITION | 주식회사 대웅제약 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023113487-A1 | DOSAGE REGIMEN FOR FEXUPRAZAN INJECTION COMPOSITION | 주식회사 대웅제약 | 2023-06-22 | — | — | WO | disclosed |
| CN-115772110-A | Method for preparing potassium ion competitive retarder non-surazan intermediate | 沈阳药科大学 | 2023-03-10 | — | — | CN | disclosed |
| CN-112094219-B | Method for preparing intermediate of potassium ion competitive retarder | 广东莱佛士制药技术有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-112094219-B | Method for preparing intermediate of potassium ion competitive retarder | 广东莱佛士制药技术有限公司 | 2022-08-05 | — | — | CN | disclosed |
| WO-2022146970-A1 | METHODS OF METABOLIZING METOPIMAZINE AND ITS SALTS | NEUROGASTRX, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022051979-A1 | METHOD FOR PREPARING POTASSIUM ION COMPETITIVE BLOCKER INTERMEDIATE | 广东莱佛士制药技术有限公司 | 2022-03-17 | — | — | WO | disclosed |
| WO-2022051979-A1 | METHOD FOR PREPARING POTASSIUM ION COMPETITIVE BLOCKER INTERMEDIATE | 广东莱佛士制药技术有限公司 | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268862-A1 | POTASSIUM-COMPETITIVE ACID BLOCKERS FOR THE TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS | SLC10A2, GIPR, SLC9A1 | HTR6 3169/4885DRD2 4646/4885MEN1 254/4885 |
| US-20250313559-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | TNNI3, TNNT2, NDUFB3 | HTR6 1455/4885DRD2 680/4885MEN1 2959/4885 |
| US-20250302811-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | TNNI3, TNNT2, NDUFB3 | HTR6 1455/4885DRD2 680/4885MEN1 2959/4885 |
| US-20260060966-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | ALB, REN, TTR | HTR6 1382/4885DRD2 1044/4885MEN1 3129/4885 |
| US-20260048041-A1 | COMPOSITION FOR REMOVING HELICOBACTER PYLORI COMPRISING ZASTAPRAZAN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CEL, PGC, SLC30A5 | HTR6 2372/4885DRD2 4283/4885MEN1 4701/4885 |
| US-20260027091-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | ALB, REN, TTR | HTR6 1553/4885DRD2 1116/4885MEN1 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.